Trial Profile

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Sep 2015 According to Merck & Co. media release, supplemental NDA for aprepitant (EMEND) in combination with other antiemetics has been approved by the US FDA for use in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg for the prevention of chemotherapy induced nausea and vomiting based partly on data from this trial.
22 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
30 Apr 2012 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com